The ERBB3 receptor in cancer and cancer gene therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• ERBB3, an epidermal growth factor receptor (EGFR) family member, possesses a functionally defective tyrosine kinase domain.
• ERBB3 activation occurs through neuregulins, other receptors, kinases, and novel mechanisms.
• ERBB3 signaling interfaces with critical pathways like phosphoinositol 3-kinase/AKT and involves interactions with multiple signaling proteins.

Purpose of the Study:

• To elucidate the multifaceted role of ERBB3 in cancer development and progression.
• To investigate the mechanisms underlying ERBB3 activation and downstream signaling.
• To evaluate therapeutic strategies targeting ERBB3 in various cancer types.

Main Methods:

• Analysis of ERBB3 expression in primary cancers.
• Mechanistic studies using cultured cancer cells.
• Investigation of small inhibitory RNA (siRNA) targeting ERBB3 and AKT.

Main Results:

• ERBB3 is implicated in the causation or sustenance of numerous cancers, including breast, ovarian, prostate, lung, and colon cancers.
• High ERBB3 activity is linked to therapeutic escape from treatments targeting other ERBBs in lung and breast cancers.
• siRNA targeting ERBB3 or AKT demonstrates therapeutic potential in lung adenocarcinoma models.

Conclusions:

• ERBB3 has a significant and increasingly recognized role in cancer etiology and progression.
• ERBB3 contributes to treatment resistance, highlighting its importance as a therapeutic target.
• Targeting ERBB3, for instance, via siRNA, represents a promising strategy for specific cancer treatments like lung adenocarcinoma.